Chelsea LoCascio


Rugo Covers Scope of Recent Breast Cancer Advances

December 6th 2017

Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.

Expert Discusses Guidelines, Next Steps With MPNs

December 4th 2017

Brady L. Stein, MD, discusses the differences between the types of MPNs, the NCCN guideline changes, and the important role of JAK inhibitors.

Expert Emphasizes Appropriate Diagnosis, Staging of T-Cell Lymphomas

December 1st 2017

Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.

Better Patient Selection Needed for AML Therapies

November 30th 2017

Alexander E. Perl, MD, discusses the future of FLT3 inhibitors, current obstacles with treating patients with acute myeloid leukemia, and what pivotal trial results the community can expect to hear in the coming months.

Challenges in mCRPC Landscape Surround Sequencing, Biomarkers, and PARP Inhibition

November 22nd 2017

Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.

Emerging Developments in NETs, Liver Cancer

November 21st 2017

Scott Paulson, MD, discusses developments with NETs and liver cancer.

Prostate Cancer Paradigm Expanding With Ongoing Research

November 15th 2017

Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.

Expert Discusses Degarelix and Other Developments in Prostate Cancer

November 14th 2017

Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

Questions Remain With CAR-T's, Checkpoints in Hematologic Malignancies

November 14th 2017

Leo I. Gordon, MD, discusses promising advances and lingering challenges with novel treatments for patients with hematologic malignancies.

Personalized Medicine Moving to Forefront of Hematologic Malignancies

November 3rd 2017

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

Expert Expands on Decision-Making Impact of Genetic Testing in Breast Cancer

November 1st 2017

Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.

Expert Raises QoL Concerns With Adjuvant Hormonal Therapy in ER+ Breast Cancer

October 31st 2017

Michelle E. Melisko, MD, discusses a variety of pivotal trials with adjuvant hormonal therapy and other developments in the treatment of patients with ER-positive breast cancer.

Immunotherapy, PARP Inhibitors Picking Up Steam in TNBC Pipeline

October 30th 2017

Howard "Skip" A. Burris, MD, discusses the ongoing research with PARP inhibitors and the advances in immunotherapy for patients with triple-negative breast cancer.

CDK4/6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care

October 27th 2017

Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.